ProCE Banner Activity

Clinical Insights to Improve NSCLC Care: Expert Guidance on Personalizing Therapy in an Era of Rapidly Increasing Complexity

Multimedia
In this Virtual Presentation, Melissa L. Johnson, MD, discusses current expert treatment recommendations for 3 key patient scenarios in the rapidly evolving therapeutic landscape of advanced NSCLC. Afterwards, download the slides and use the treatment decision tool for your practice.

Released: June 08, 2018

Share

Faculty

Melissa L. Johnson

Melissa L. Johnson, MD

Assistant Professor
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center 
Northwestern University
Assistant Attending
Divison of Hematology/Oncology
Northwestern Memorial Hospital
Chicago, Illinois

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Celgene TEXT Only

Genentech TEXT Only

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Takeda Oncology

Learning Objectives

  • Plan individualized treatment strategies based on histology as well as patient age/fitness, comorbidities, and preferences
  • Apply the available data, treatment guidelines, and expert recommendations to select therapy for NSCLC positive for sensitizing EGFR mutations, ALK or ROS1 gene rearrangements, or high PD-L1 expression

Faculty Disclosure

Primary Author

Melissa L. Johnson, MD

Assistant Professor
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center 
Northwestern University
Assistant Attending
Divison of Hematology/Oncology
Northwestern Memorial Hospital
Chicago, Illinois

Melissa L. Johnson, MD, has no real or apparent conflicts of interest to report.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, Ph D, has no real or apparent conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin L. Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.